Marshall Wace LLP acquired a new position in Revolution Medicines, Inc. (NASDAQ:RVMD) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 35,031 shares of the company’s stock, valued at approximately $1,112,000.
Several other institutional investors and hedge funds have also recently bought and sold shares of RVMD. Carolinas Wealth Consulting LLC purchased a new position in shares of Revolution Medicines in the 2nd quarter worth about $32,000. Nisa Investment Advisors LLC boosted its holdings in shares of Revolution Medicines by 64.7% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,470 shares of the company’s stock worth $78,000 after purchasing an additional 970 shares in the last quarter. Great West Life Assurance Co. Can lifted its stake in shares of Revolution Medicines by 133.2% in the 2nd quarter. Great West Life Assurance Co. Can now owns 2,526 shares of the company’s stock valued at $80,000 after acquiring an additional 1,443 shares during the last quarter. FORA Capital LLC bought a new stake in shares of Revolution Medicines in the 2nd quarter valued at about $82,000. Finally, Ameritas Investment Partners Inc. lifted its stake in shares of Revolution Medicines by 34.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,657 shares of the company’s stock valued at $148,000 after acquiring an additional 1,183 shares during the last quarter. Hedge funds and other institutional investors own 95.47% of the company’s stock.
Shares of NASDAQ:RVMD opened at $28.87 on Thursday. Revolution Medicines, Inc. has a 52-week low of $21.78 and a 52-week high of $56.18. The firm has a market capitalization of $2.13 billion, a P/E ratio of -12.18 and a beta of 1.94. The stock has a 50 day moving average price of $29.72 and a 200-day moving average price of $30.04.
RVMD has been the subject of a number of recent research reports. HC Wainwright boosted their target price on Revolution Medicines from $31.00 to $38.00 and gave the company a “buy” rating in a research note on Friday, November 12th. Guggenheim lowered their target price on Revolution Medicines from $52.00 to $34.00 and set a “buy” rating for the company in a research note on Thursday, August 12th. Stifel Nicolaus initiated coverage on Revolution Medicines in a research note on Wednesday, September 22nd. They issued a “hold” rating and a $34.00 target price for the company. SVB Leerink lowered their target price on Revolution Medicines from $46.00 to $38.00 and set an “outperform” rating for the company in a research note on Thursday, August 12th. Finally, The Goldman Sachs Group lowered Revolution Medicines from a “buy” rating to a “neutral” rating and lowered their price target for the company from $49.00 to $27.00 in a research report on Thursday, August 12th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, Revolution Medicines has a consensus rating of “Buy” and an average price target of $35.83.
Revolution Medicines Profile
Revolution Medicines, Inc, a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors.
Featured Story: What is the FTSE 100 index?
Want to see what other hedge funds are holding RVMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revolution Medicines, Inc. (NASDAQ:RVMD).
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.